Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Naloxone

An opioid antagonist developed and patented in 1961 by Jack Fishman and Mozes Lewenstein, approved in the United States in 1971: it is used to rapidly reverse the effects of opioids, especially respiratory depression. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It also became a research tool: in 1978 a study on pain after dental surgery showed that naloxone reduced the placebo effect, a sign that placebo works partly through endorphins.

Naloxone HydrochlorideGo to the active ingredient →
Naloxone-d5Isotopically labelledNaloxone-d5Cat. No. P-N017-014CAS 1261079-38-2

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.